GMAB vs. CPRX
Compare and contrast key facts about Genmab A/S (GMAB) and Catalyst Pharmaceuticals, Inc. (CPRX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GMAB or CPRX.
Correlation
The correlation between GMAB and CPRX is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
GMAB vs. CPRX - Performance Comparison
Loading data...
Key characteristics
GMAB:
53.55%
CPRX:
59.23%
GMAB:
-10.16%
CPRX:
-6.34%
GMAB:
-10.16%
CPRX:
-3.83%
Fundamentals
GMAB:
$12.12B
CPRX:
$2.85B
GMAB:
$1.84
CPRX:
$1.31
GMAB:
10.52
CPRX:
17.84
GMAB:
1.02
CPRX:
0.00
GMAB:
0.57
CPRX:
5.80
GMAB:
15.00
CPRX:
3.59
GMAB:
$18.10B
CPRX:
$534.65M
GMAB:
$17.26B
CPRX:
$451.07M
GMAB:
$6.35B
CPRX:
$177.46M
Returns By Period
GMAB
N/A
N/A
N/A
N/A
N/A
N/A
CPRX
N/A
N/A
N/A
N/A
N/A
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GMAB vs. CPRX — Risk-Adjusted Performance Rank
GMAB
CPRX
GMAB vs. CPRX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Genmab A/S (GMAB) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
GMAB vs. CPRX - Dividend Comparison
Neither GMAB nor CPRX has paid dividends to shareholders.
Drawdowns
GMAB vs. CPRX - Drawdown Comparison
The maximum GMAB drawdown since its inception was -10.16%, which is greater than CPRX's maximum drawdown of -6.34%. Use the drawdown chart below to compare losses from any high point for GMAB and CPRX. For additional features, visit the drawdowns tool.
Loading data...
Volatility
GMAB vs. CPRX - Volatility Comparison
Loading data...
Financials
GMAB vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between Genmab A/S and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GMAB vs. CPRX - Profitability Comparison
GMAB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Genmab A/S reported a gross profit of 673.00M and revenue of 715.00M. Therefore, the gross margin over that period was 94.1%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a gross profit of 123.51M and revenue of 141.42M. Therefore, the gross margin over that period was 87.3%.
GMAB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Genmab A/S reported an operating income of 188.00M and revenue of 715.00M, resulting in an operating margin of 26.3%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported an operating income of 63.37M and revenue of 141.42M, resulting in an operating margin of 44.8%.
GMAB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Genmab A/S reported a net income of 195.00M and revenue of 715.00M, resulting in a net margin of 27.3%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a net income of 56.74M and revenue of 141.42M, resulting in a net margin of 40.1%.